Peer-Reviewed Study Shows BillionToOne's Tissue-Free Assay Matches or Beats Tumor-Informed Monitoring
BLLN sits 61% above its 52-week low of $61.96.
Summary
BillionToOne published the first peer-reviewed head-to-head study of its Northstar Response assay against a tumor-informed ctDNA test. The study, in The Journal of Liquid Biopsy, evaluated 169 paired samples from 61 patients and found 94% concordance in treatment response direction across 71 sequential pairs. In all discordant cases, Northstar Response matched the clinical ground truth from imaging or biopsy, suggesting the tumor-informed comparator produced false positives or negatives. This validates the company's tissue-free approach for monitoring advanced cancers without needing a biopsy, potentially accelerating treatment decisions. The data strengthens the commercial case for Northstar Response as a differentiated liquid biopsy product.
At the time of this announcement, BLLN was trading at $99.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $61.96 to $150.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.